Alban Juan, Kennedy Kathleen, Hulbert Alicia, Lighter Melani, Pasquinelli Mary, Rubinstein Israel, Ghelani Seema, Clayburn Andrew, Feldman Lawrence E
Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.
Division of Hematology/Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois.
Semin Oncol. 2022 Jun;49(3-4):261-264. doi: 10.1053/j.seminoncol.2022.06.012. Epub 2022 Aug 28.
Recommending video-assisted thoracic surgery (VATS) over open thoracotomy to patients with early-stage non-small-cell lung cancer (NSCLC) is controversial. Accordingly, we reviewed randomized comparative studies to determine the risks and benefits of VATS lobectomy. Electronic searches on PubMed with standard search terms revealed 97 comparative studies published between 1990 and 2022. Of those, only 5 were randomized controlled clinical trials (RCT) and 1 is still ongoing although initial data has been published as an abstract form. A total of 918 patients were evaluated in 5 RCT's. All studies included patients with known or suspected primary lung cancer randomized in a 1:1 ratio to VATS or thoracotomy. Between 2 studies, reports of 1-year, 3-year and 5-year overall survival were found to be similar across surgical modalities. Additionally, no differences were found in the rates of locoregional and distant recurrence. Three studies reported no statistical differences in the number of hilar and mediastinal lymph nodes sampled. Two studies found decreased length of stay following VATS (4 days v 5 days, P = 0.027 and P = 0.008), while 2 found no difference. Increased in-hospital complications were seen in 2 studies (P = 0.008 and P = 0.039). VATS was associated with decreased pain scores, better self-reported QOL at 52 weeks (P = 0.014). Few randomized clinical trials comparing VATS lobectomy to open thoracotomy and lobectomy in early stage NSCLC have been reported. These studies suggest that VATS lobectomy offers similar outcomes with decreased in-hospital complications, pain, length of stay, and improved physical functioning when compared to thoracotomy.
对于早期非小细胞肺癌(NSCLC)患者,推荐采用电视辅助胸腔镜手术(VATS)而非开胸手术存在争议。因此,我们回顾了随机对照研究,以确定VATS肺叶切除术的风险和益处。使用标准检索词在PubMed上进行电子检索,共检索到1990年至2022年间发表的97项比较研究。其中,只有5项是随机对照临床试验(RCT),1项仍在进行中,不过其初始数据已以摘要形式发表。5项RCT共评估了918例患者。所有研究均纳入已知或疑似原发性肺癌患者,按1:1比例随机分为VATS组或开胸手术组。在2项研究中,发现不同手术方式的1年、3年和5年总生存率报告相似。此外,局部区域复发率和远处复发率也无差异。3项研究报告称,两组在肺门和纵隔淋巴结采样数量上无统计学差异。2项研究发现VATS术后住院时间缩短(分别为4天对5天,P = 0.027和P = 0.008),而另外2项研究未发现差异。2项研究显示住院并发症增加(P = 0.008和P = 0.039)。VATS与疼痛评分降低、52周时自我报告的生活质量改善相关(P = 0.014)。很少有关于早期NSCLC患者VATS肺叶切除术与开胸肺叶切除术比较的随机临床试验报告。这些研究表明,与开胸手术相比,VATS肺叶切除术具有相似的疗效,同时可降低住院并发症、疼痛、缩短住院时间并改善身体功能。